add site
services
publishers
database
health videos
toolbar
stats
live show
health store
more stuff
JOIN/LOGIN
| advertise add site services publishers database health videos
| | about toolbar stats live show health store more stuff JOIN/LOGIN |
Endo Pharmaceuticals endo.com |
Endo Pharmaceuticals Inc. is an American pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997. Three DuPont Merck executives (Carol A. Ammon, Chairman, President & CEO, and Mariann T. MacDonald, Executive Vice President, Operations, along with another colleague) purchase all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including Percocet and Percodan. The new company was called Endo Pharmaceuticals Inc. Endo acquired Algos Pharmaceutical Corporation through a merger in July 2000 and began to trade publicly (NASDAQ: ENDP). Endo Pharmaceuticals successfully completed a secondary offering for a total of 12,925,000 shares of its common stock in Oct 2001. The net proceeds were used to pay existing bank debt. Endo is a specialty pharmaceutical company engaged in the research, development, sale and marketing of prescription pharmaceuticals used primarily to treat and manage pain. Endo rents some lab space from Novartis, at the Novartis production facility in Lincoln, Nebraska. At this lab, there is quality control testing of the Endo products that are produced on-site. At this particular Novartis production site, products such as TheraFlu, Triaminic and Buckley's are produced, as well as all of the Excedrin distributed across the entire nation. In 2009, Endo bought Indevus Pharmaceuticals to diversify into Endocrinology and Oncology.[1] The company expects to enter the male Hypogonadism market later in 2009 with Nebido.[2] [edit] Personnel
[edit] Products
Source:[4] [edit] References
| ||||||||||||
| ↑ top of page ↑ | about thumbshots |
